Trump administration wants Obamacare subsidy case put on hold, again | Reuters
By Lawrence Hurley and Yasmeen Abutaleb | WASHINGTON WASHINGTON The Trump administration on Monday asked that a major federal court case weighing the fate of the Obamacare cost-sharing subsidies be put on hold again, leaving billions of dollars in payments to insurers up in the air for 2017 and 2018. In a joint filing with the U.S. House of Representatives submitted to the U.S.
By Lawrence Hurley and Yasmeen Abutaleb
WASHINGTON The Trump administration on Monday asked that a major federal court case weighing the fate of the Obamacare cost-sharing subsidies be put on hold again, leaving billions of dollars in payments to insurers up in the air for 2017 and 2018. In a joint filing with the U.S. House of Representatives submitted to the U.S. Court of Appeals for the District of Columbia Circuit, the administration and Republican lawmakers asked for a second 90-day extension.The subsidies are available to low-income Americans who buy individual health insurance on the exchanges created under Obamacare, former President Barack Obama's signature healthcare law. President Donald Trump and Republican lawmakers want to repeal and replace the law and are working on legislation to overhaul it that would also secure the subsidy funding during a transition period, but it is not clear if or when they will pass it.
The two sides said they wanted more time because they are discussing measures that would no longer require a judicial decision, including this new healthcare legislation.In the meanwhile, insurers that are trying to set premium rates for insurance plans to be sold in 2018 are running up against deadlines and have repeatedly asked Congress to fund the subsidies during the transition.The legal case, was filed by the Republican-led House against the Obama administration to cut off the subsidy payments.
A lower court had ruled in favor of the lawmakers, saying that Congress must appropriate the money for these subsidies and that the government could not simply pay for them in the way it does now. Insurers and medical groups reiterated their view on Monday after the court filing about continuing the payments, which amount to about $7 billion this year and help low-income consumers pay for out-of-pocket medical costs.
"Uncertainty is destabilizing the market and leading health plans to raise their rates for 2018 to account for the political risk brought on by Congress and the administration through a protracted debate over the fate of these reimbursements," Margaret Murray, chief executive officer of the Association for Community Affiliated Plans, said in a statement.While the proposed legislation from the House would keep the payments through 2019, President Donald Trump has said that he can stop paying the subsidies at any time. That has insurers concerned that the monthly government payments could end and leave them exposed financially. Several insurers, including Aetna Inc and Humana Inc, have already exited the Obamacare marketplace for 2018. Credit Suisse analyst Scott Fidel said that insurers such as Centene Corp and Molina Healthcare Inc that focus on the low-income families that qualify for these subsidies have the most at risk. Centene shares were off 1.8 percent at $73.70 and Molina fell 1.5 percent to $66.35. (Reporting by Lawrence Hurley, Yasmeen Abutaleb and Caroline Humer in New York; Editing by Jonathan Oatis and Lisa Shumaker)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.
By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month
By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.